Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-02-28

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Nasal/nasal type NK-T-cell lymphoma is a rare and severe type of non-Hodgkin's lymphoma (NHL) more frequent in Asia than in western countries. When localised, radiotherapy seems to be the best treatment. When radiotherapy cannot be used because of dissemination or relapse, chemotherapy protocols used for other types of NHL give poor results and survival is poor. Recently papers from China and Japan reported the efficacy of a drug: l-asparaginase, usually used to treat acute lymphoblastic leukemia. In vitro a selective apoptosis of NK-cell tumours by l-asparaginase was shown on tumour cell lines and samples.

The investigators propose a phase II protocol for patients with refractory or relapsing nasal/nasal type NK-T-cell lymphoma using a regimen combining l-asparaginase, methotrexate and dexamethasone. Biological studies will be conducted trying to find factors which could predict responses to this chemotherapy.

Since january 2009, the study concerns all patients with nasal/nasal type NK-T-cell lymphoma who have not received asparaginase before.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma

NCT02825147

Nasal Type Extranodal NK/T-Cell Lymphoma

COMPLETED PHASE2

Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV Non-Hodgkin's Lymphoma

NCT00003501

Non-hodgkins Lymphoma

TERMINATED PHASE2

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT07123454

B-cell Non-Hodgkin Lymphoma

RECRUITING PHASE1/PHASE2

A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma

NCT07000617

NK/T Cell Lymphoma

RECRUITING PHASE2

Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma

NCT00003498

Non Hodgkin Lymphoma

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Objective:

* Determine the overall and complete response rate

Secondary Objectives:

* To evaluate survival without progression
* To evaluate total survival.
* To evaluate the tolerance and the side effects of the treatment.
* To evaluate the duration and the mode of hospitalization of the patients treated by this therapeutic association.
* To constitute a bank of biological samples - serum, tumoral, ADN, ARN to allow prognostic studies implying virus EBV, p53, CD94, C-kit and asparagine synthetase gene in order to better understand the mechanisms of the cancerogenesis of this variety of cytotoxic LNH and to identify the predictive factors of response to the asparaginase.

Sampling:

For each patient included in the protocol, the following sampling will be carried out with the diagnosis:

* Biopsy,
* Medullary biopsy
* Medullary aspiration
* blood: 3 tubes of 7 ml on EDTA and 3 tubs of 7 ml with heparin

Treatment:

All the patients included will receive three cures separated by 3 weeks (J1, J22, J43):

* J1: Methotrexate 3 gr/m2
* J2, J4, J6 and J8: Kidrolase® 6000 u/m2
* J1 with J4: Dexamethasone 40 mg (20 mg if age \> 70 years)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoma, Non-Hodgkin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Kidrolase

6000 u/ m2 IM at J2, J4 and J6 and J8. 3 to 6 cycles.

Intervention Type DRUG

Methotrexate

3 gr/m2 at J1

Intervention Type DRUG

Dexamethasone

40 mg/ per os at J1, J2 and J4.

Intervention Type DRUG

Erwinase

In case of allergy to Kidrolase

20000 u/m2 en IM at J2, J4, J6 et J8. 3 to 6 cycles

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients with relapsing/refractory T-NK/NK lymphoma:

* Ages 18 years and above
* Patients must have a diagnosis of NK-cell (or T-NK) non-Hodgkin's lymphoma, nasal or nasal-type.
* Stage I, II, III, or IV disease
* Creatinine less than 3 x upper limit of normal (ULN)
* Able to give informed consent
* No prior treatment with asparaginase

Patients with T-NK/NK lymphoma (de novo patients ):

* Ages 18 years and above
* Patients must have a diagnosis of NK-cell (or T-NK) non-Hodgkin's lymphoma, nasal or nasal-type.
* Stage I, II, III, or IV disease
* Creatinine less than 3 x upper limit of normal (ULN)
* Able to give informed consent
* no prior chemotherapy or radiotherapy

Exclusion Criteria

* Patients who are pregnant or nursing
* Any factor which might limit the patient's ability to provide informed consent
* Liver insufficiency
* Evolutive thrombosis

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No